TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Manufacturing Scale Up of Lead Ox-1 Development Programme

Alderley Park, 17 July 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, provides an update on key activity in its Ox-1 development programme.

At the recent AGM the Company gave an update on its lead asset Ox-1, TheraCryf's orexin 1 antagonist in addictive behaviours, highlighting the on-track progress made following the fundraising in March of this year to take the programme to clinical readiness.

The Company now reports that manufacturing and early development partner, Pharmaron, has initiated the manufacturing scale up of the active pharmaceutical ingredient (API) of the lead programme, Ox-1, on-time and to-plan. The production of the demonstration and toxicology batches, at 0.5kg and 10kg scale, respectively, are key milestones in the development programme. These batches will produce sufficient quantities of product for formulation, characterisation and toxicology, all of which are essential for inclusion in the regulatory documentation for obtaining permission to conduct trials in people.

Dr Helen Kuhlman, CBO of TheraCryf commented:

"Manufacturing at scale for the first time represents a major step forward in any development programme at this stage. The start of this activity by our early development partner on time is another demonstration of our confidence in both the programme and our management of it. Unlocking the considerable future value of our addiction programme is our first priority given the large addressable market for our Ox-1 asset."

-Ends-

Enquiries

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders.  The Company has sourced know-how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.